2020
Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE)
Callstrom MR, Woodrum DA, Nichols FC, Palussiere J, Buy X, Suh RD, Abtin FG, Pua BB, Madoff DC, Bagla SL, Papadouris DC, Fernando HC, Dupuy DE, Healey TT, Moore WH, Bilfinger TV, Solomon SB, Yarmohammadi H, Krebs HJ, Fulp CJ, Hakime A, Tselikas L, de Baere T. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). Journal Of Thoracic Oncology 2020, 15: 1200-1209. PMID: 32151777, PMCID: PMC9201766, DOI: 10.1016/j.jtho.2020.02.022.Peer-Reviewed Original ResearchConceptsOverall survival ratePulmonary metastasesPercutaneous cryoablationSurvival rateLocal recurrence-free survivalGrade 4 eventsPleural catheter placementMetastatic lung tumorsPhase 2 studyKaplan-Meier methodRecurrence-free survivalRate of pneumothoraxKaplan-Meier estimatesKey inclusion criteriaQuality of lifeComplication eventsExtrapulmonary cancersMetastatic diseasePerformance statusInitial treatmentRecurrent tumorsCatheter placementLung metastasesMulticenter studyCryoablation treatment
2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2011
High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survivalMajor hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009, 145: 399-405. PMID: 19303988, DOI: 10.1016/j.surg.2008.10.009.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationMajor hepatic resectionPreoperative PVEPVE groupHepatic resectionPortal vein embolizationHepatocellular carcinomaPerioperative outcomesDFS ratesPerioperative deathsVein embolizationSurvival rateDisease-free survival ratesPreoperative transarterial chemoembolizationOverall postoperative complicationsRemnant liver volumeImproved perioperative outcomesOverall survival rateAmerican Joint CommitteeHepatitis B virusHepatitis C virusPerioperative mortalityPerioperative riskPostoperative complicationsOverall survival
2007
Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomy